Cargando…

Flourish of Proton and Carbon Ion Radiotherapy in China

Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the w...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Li, Xiaoman, Yang, Jiancheng, Wang, Sicheng, Tang, Meitang, Xia, Jiawen, Gao, Yunzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/
https://www.ncbi.nlm.nih.gov/pubmed/35237518
http://dx.doi.org/10.3389/fonc.2022.819905
_version_ 1784659750606077952
author Li, Yue
Li, Xiaoman
Yang, Jiancheng
Wang, Sicheng
Tang, Meitang
Xia, Jiawen
Gao, Yunzhe
author_facet Li, Yue
Li, Xiaoman
Yang, Jiancheng
Wang, Sicheng
Tang, Meitang
Xia, Jiawen
Gao, Yunzhe
author_sort Li, Yue
collection PubMed
description Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the world. At present, five particle radiotherapy institutes have been built and are receiving patient in China, mainly including Wanjie Proton Therapy Center (WPTC), Shanghai Proton Heavy Ion Center (SPHIC), Heavy Ion Cancer Treatment Center (HIMM), Chang Gung Memorial Hospital (CGMH), and Ruijin Hospital affiliated with Jiao Tong University. Many cancer patients have benefited from ion therapy, showing unique advantages over surgery and chemotherapy. By the end of 2020, nearly 8,000 patients had been treated with proton, carbon ion or carbon ion combined with proton therapy. So far, there is no systemic review for proton and carbon ion therapy facility and clinical outcome in China. We reviewed the development of proton and heavy ion therapy, as well as providing the representative clinical data and future directions for particle therapy in China. It has important guiding significance for the design and construction of new particle therapy center and patients’ choice of treatment equipment.
format Online
Article
Text
id pubmed-8882681
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88826812022-03-01 Flourish of Proton and Carbon Ion Radiotherapy in China Li, Yue Li, Xiaoman Yang, Jiancheng Wang, Sicheng Tang, Meitang Xia, Jiawen Gao, Yunzhe Front Oncol Oncology Proton and heavy ion therapy offer superior relative biological effectiveness (RBE) in the treatment of deep-seated tumors compared with conventional photon radiotherapy due to its Bragg-peak feature of energy deposition in organs. Many proton and carbon ion therapy centers are active all over the world. At present, five particle radiotherapy institutes have been built and are receiving patient in China, mainly including Wanjie Proton Therapy Center (WPTC), Shanghai Proton Heavy Ion Center (SPHIC), Heavy Ion Cancer Treatment Center (HIMM), Chang Gung Memorial Hospital (CGMH), and Ruijin Hospital affiliated with Jiao Tong University. Many cancer patients have benefited from ion therapy, showing unique advantages over surgery and chemotherapy. By the end of 2020, nearly 8,000 patients had been treated with proton, carbon ion or carbon ion combined with proton therapy. So far, there is no systemic review for proton and carbon ion therapy facility and clinical outcome in China. We reviewed the development of proton and heavy ion therapy, as well as providing the representative clinical data and future directions for particle therapy in China. It has important guiding significance for the design and construction of new particle therapy center and patients’ choice of treatment equipment. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882681/ /pubmed/35237518 http://dx.doi.org/10.3389/fonc.2022.819905 Text en Copyright © 2022 Li, Li, Yang, Wang, Tang, Xia and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yue
Li, Xiaoman
Yang, Jiancheng
Wang, Sicheng
Tang, Meitang
Xia, Jiawen
Gao, Yunzhe
Flourish of Proton and Carbon Ion Radiotherapy in China
title Flourish of Proton and Carbon Ion Radiotherapy in China
title_full Flourish of Proton and Carbon Ion Radiotherapy in China
title_fullStr Flourish of Proton and Carbon Ion Radiotherapy in China
title_full_unstemmed Flourish of Proton and Carbon Ion Radiotherapy in China
title_short Flourish of Proton and Carbon Ion Radiotherapy in China
title_sort flourish of proton and carbon ion radiotherapy in china
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882681/
https://www.ncbi.nlm.nih.gov/pubmed/35237518
http://dx.doi.org/10.3389/fonc.2022.819905
work_keys_str_mv AT liyue flourishofprotonandcarbonionradiotherapyinchina
AT lixiaoman flourishofprotonandcarbonionradiotherapyinchina
AT yangjiancheng flourishofprotonandcarbonionradiotherapyinchina
AT wangsicheng flourishofprotonandcarbonionradiotherapyinchina
AT tangmeitang flourishofprotonandcarbonionradiotherapyinchina
AT xiajiawen flourishofprotonandcarbonionradiotherapyinchina
AT gaoyunzhe flourishofprotonandcarbonionradiotherapyinchina